



(REVIEW ARTICLE)



A review on co-processed excipients used in direct compression of tablet dosage form

Paka Bhavana * and M Sunitha Reddy

Department of Pharmaceutics, Centre for Pharmaceutical Sciences, JNTUH UCEST, JNTUH, Hyderabad, Telangana-500085, India.

GSC Biological and Pharmaceutical Sciences, 2023, 23(01), 212–219

Publication history: Received on 06 January 2023; revised on 17 April 2023; accepted on 20 April 2023

Article DOI: <https://doi.org/10.30574/gscbps.2023.23.1.0100>

Abstract

Co-processed excipients may enhance functionality and reduce drawbacks of traditional excipients for the manufacture of tablets on a commercial scale. The following study aimed to characterize a range of co-processed excipients that may prove suitable for dispersible tablet formulations prepared by direct compression. The dosage form that is used the most is tablets. Their accessibility, simplicity of administration, consistency, and affordability are advantages. Direct compression is the most straightforward method for making tablets, despite the fact that it comes with several challenges, including those connected to the homogeneity and mass variation of the content, disintegration, dissolution, and the radial hardness of the tablets. In today's world, "co-processed excipients," which include frequently processed mixtures of fillers, binders, disintegrants, lubricants, and other excipients, are becoming more popular. Spray drying, fluid bed granulation, wet granulation, melt granulation, dry granulation, and co-crystallization are used to create these mixes. This review article lists technologies, co-processed excipients that are commercially available, and excipients that are typically utilized to make them.

Keywords: Co-processed excipients; Direct compression; Blends; Tablets; Physical characteristics

1. Introduction

The pharmaceutical industry first started to use co-processed excipients from the late 1980s, with early examples including co-processed microcrystalline cellulose and calcium carbonate, introduced in 1988, MEGGLE's co-processed cellulose and lactose (1990), and co-processed glucomannan and galactomannan (1996). The International Pharmaceutical Excipients Council (IPEC) defines excipient as "substances other than the API which have been appropriately evaluated for safety and are intentionally included in a drug delivery system". An excipient that has undergone co-processing is a combination of two or more compendial or non-compendial excipients with the goal of physically changing their properties without altering chemical properties.[1]

1.1. Advantages of co-processed excipients

- One excipient can serve many purposes.
- Overcome the excipients limitations.
- Improved organoleptic qualities.
- Displays constructive interaction.
- Improved physiochemical characteristics.
- Minimises modifications to the profile of dissolution.
- Enhanced palatability and increased tongue feel.
- Reduce unfavourable characteristics.
- Enhance the flow qualities.

* Corresponding author: Paka Bhavana

- Increasing compressibility.
- Increased potential for dilution.
- Lessen sensitivity of the lubricant.

1.2. Disadvantages of co-processed excipients

- Elevated temperature processing and specialised filling equipment are needed.
- Pre-clinical species do not always tolerate some lipidic excipients well.
- Cost of process is high due to labour costs, space costs, time, energy, and specialised equipment needs.
- Material loss throughout different processing phases.
- Drugs that are thermolabile or moisture sensitive are not good candidates.
- Long duration. [66]

2. Principle of co-processing

2.1. Particle Engineering

Solid substances are characterized by three levels of solid-state: the molecular, particle, and bulk level. These levels are closely linked to one another, in which changes in one level reflect another. The molecular level includes arrangement of molecules in the crystal lattice and includes polymorphism, pseudo-polymorphism, and amorphous state. The particle level includes particle properties such as shape, size, surface area, and porosity. The bulk level includes ensemble of particles and properties such as flowability, compressibility, and dilution potential. The scientific framework for the development of new grades of current excipients and novel combinations of existing excipients is provided by the interdependence among the levels.[1]

2.2. Steps involved in co-processing of excipients

- Selection of the excipients group to be co processed by carefully studying the material (elastic, plastic or brittle) characteristics and functionality requirements.
- Choose required proportions of excipients.
- Examine the particle size required for co processing.
- Choose a suitable drying method, such as spray drying or flash drying.




Figure 1 Steps involved in co-processing of excipients

3. Methods of co-processing

- Spray drying
- Wet granulation
- Melt extrusion
- Granulation
- Solvent evaporation
- crystallisation
- Roller drying
- Hot melt extrusion
- Co-transformation
- Milling

3.1. Spray drying

This spray drying technique allows the conversion of feed from a fluid state into dried particle. The feed can be a solution, suspension, dispersion, or emulsion. The dried product can be formed in the powders, granules, or agglomerates and these are depending upon the physical and chemical properties of feed and the dryer design final powder properties needed. It is a continuous particle processing drying operation. The spray drying process parameters like inlet air temperature, atomization air pressure, feed rate, liquid viscosity, solid content in feed, disc speed can be helped in design particle with desire characteristics. hence spray drying process can be desire as consisting of four steps:

- Atomization of the liquid into droplets.
- Contact of the droplet with the warm drying gas. [3]
- Fast evaporation of the droplets to form dry particles.
- Recovery of the dry particles from the drying gas, using a cyclone. [3]

3.1.1. Advantages of spray drying

- It is possible to associate non-miscible products in continuous operation.
- It allows blending and drying simultaneously for soluble and insoluble compound.
- Fix and protect sensitive active compound on natural carrier.
- Improves hardness and compressibility.
- Decreases disintegration time and enhances machine tableting speed. [3]

3.2. Wet granulation

Wet granulation is a conventional and simple method for co-processed adjuvant production. Fluid bed granulators and high shear mixers are two commonly used equipment used for the same. In fluid bed granulation, the powder mix is subjected to fluidization by a flow of air injected upwards through the bottom screen of the granulator. The binding solution is sprayed in the opposite direction to the air flow on the powder bed. The solid particles are mixed with the liquid droplets and hit the bed which results in adhesion and eventually the formation of granules. Partial drying by the fluidizing air occurs continuously during granulation. In high-shear granulation, an impeller keeps the powder in agitation in a closed vessel. The binder solution is sprayed from the top. Development of large agglomerates is prevented by high shear force. With the new single-pot technology, drying occurs in the same system. The granules formed are understandably denser than those obtained in fluid bed granulation. [2,6]

3.3. Melt extrusion

Melt extrusion is a process of formation of small beads, pellets from the molten mass which extruded through extruder. Extruders consist of four distinct parts:

- An opening though which material enters the barrel that may have a hopper that is filled with the materials to be extruded.
- A conveying section (process section), which forms the barrel and the screws that transport, and where applicable, mix the material.
- An orifice (die) for shaping the material as it leaves the extruder.
- Downstream auxiliary equipment for cooling, cutting and/or collecting the finished product. [1,3]

3.4. Granulation

Granulation is the act or process of forming or crystallizing into grains. Granules typically have a size range between 0.2 to 4.0 mm depending on their use. In pharmaceutical industry, two types of granulation technologies are employed, namely, Wet Granulation and Dry Granulation. Wet granulation is the most preferred method for coprocessing.[1]

3.5. Solvent evaporation

This process is carried out in a liquid manufacturing vehicle. The coating excipient is dissolved in a volatile solvent, which is immiscible with the liquid manufacturing vehicle phase. A core excipient material to be microencapsulated is dissolved or dispersed in the coating polymer solution. With agitation, the core coating material mixture is dispersed in the liquid manufacturing vehicle phase to obtain the proper size microcapsule. The mixture is then heated (if necessary) to evaporate the solvent. Once all the solvent is evaporated, the liquid vehicle temperature is reduced to ambient temperature (if needed) with continued agitation. At this stage, the microcapsules can be used in suspension form, coated on to substrates or isolated as powders. The core materials may be either water -soluble or water - insoluble materials.[1]

3.6. Crystallization

Crystallization is the natural or artificial process of formation of solid crystals precipitating from a solution, melted or more rarely deposited directly from a gas. Crystallization is also a chemical solid– liquid separation technique, in which mass transfer of a solute from the liquid solution to a pure solid crystalline phase occurs. Procedure: For crystallization to occur from a solution it must be supersaturated. This means that the solution must hold more solute entities dissolved than it would have under the equilibrium. This can be achieved by various methods, with

- Solution cooling,
- Addition of a second solvent to reduce the solubility of the solute (technique known as antisolvent or drown-out),
- Chemical reaction
- Change in pH being the most common methods used in industrial practice [1]

3.7. Roller drying

A roller dryer is used to dry the homogeneous solution or dispersion containing the pre-blended excipients. Meggelaars et al. (1996) applied this technique to co-process lactose with sorbitol and lactitol. The temperature used was sufficiently high to obtain a product that consists principally of β -lactose in crystalline form.[2]

3.8. Hot melt extrusion

Hot melt extrusion uses heat with a temperature greater than 80 °C. This method is not suitable for thermos labile materials. The excipients are melted and then pressurized through the die and solidify into a variety of shapes. The solvent is not needed in the process as the molten polymer can function as a thermal binder.[2,6]

3.9. Co-transformation

Co-transformation technique involves the application of heat or solvent effect to “open-up” that is for swelling the particle of one excipient. The other excipients are incorporated into the “opened-up” structure of the forementioned excipient. The augmented excipient strengthens the functionality of the end product.[2,6]

3.10. Milling

A roller mill, ball mill, bead mill, millstone mill, jet mill or a hammer mill can be used to perform milling or dry grinding. The excipients are premixed and passed through a high-speed milling machine. During the process of milling, the particles meet each other and form bonds when they are subjected to force to mill or pass through the screen. Rao et al. (2012) applied this technique to co-process cross-linked polyvinylpyrrolidone and calcium silicate.[2,6]

4. Co-processed excipients used in direct compression of tablet dosage forms

Direct compression (DC) is a commonly used method for the preparation of oral solid dosage forms such as tablets. Benefits include avoiding process steps such as wet or dry granulation, providing less variable dissolution profiles compared to granulation methods, reduced wear and tear of punches, improved stability of API and reduced microbial contamination. The challenge associated with the development of tablets using Direct Compression is often the sub-optimal compression and flow properties of the active pharmaceutical ingredient, especially if the drug loading in the formulation is very high. As such, the feasibility of the DC route is highly dependent on the physicochemical properties of the API which determine its flow and compression behavior the formulation, especially when these constitute a large proportion of the tablet. When the loading and properties of the API allow for DC, selection of excipients becomes a key consideration in the development of tablets by DC. To ensure formulation success, it is necessary to fully characterize and understand the flow and compression properties of the excipients.

At present, conventional grades of excipients do not always exhibit the necessary flowability, compressibility, high dilution potential and homogeneity to accommodate different APIs DC. The extensive development process for a new product typically involves multiple investigations using a range of excipient material grades and suppliers. One way to ease the development process could be to use co-processed excipients that are suitable for commercial scale manufacture. Co-processed excipients are the combination of two or more excipients, prepared by processes such as spray drying, wet granulation and co-crystallization.

Co-processing of excipients physically modifies the individual materials without altering their chemical structure. Co-processed excipients may be advantageous in a number of ways providing improved functionality in comparison to physical mixtures of individual excipient components combining a range of different materials such as plastic and brittle deforming materials, which prevents storage of excess elastic energy during compression, hence reducing the risk of capping and lamination during compression and accelerating the speed that new products can enter the market without the need for extensive and expensive testing. One drawback of co-processed excipients is that they are not always recognized by the different pharmacopoeias. An area where co-processed excipients may have a particular advantage is in the development and manufacture of dispersible tablets. Dispersible tablets are intended to be dispersed in a liquid (typically water) before administration giving a homogeneous dispersion.

Table 1 Commercially available Co-processed Excipients Used in Direct Compression

| Co-processed excipients | Trade name | Manufacturer | Advantages |
|---|--------------------|--------------------|---|
| Mannitol, hydroxypropyl methylcellulose | Pearlitol | Roquette | Used in direct compression of controlled oral tablets, binder |
| Microcrystalline cellulose, colloidal silicon dioxide | Dicom sanaq® sp206 | Pharma trans sanaq | Used in direct compression of hygroscopic and moisture sensitive apis and has excellent flow properties |
| Lactose monohydrate, cellulose micro crystalline | Dicom sanaq ml 011 | Pharma trans sanaq | Enhance the stability and effectiveness during manufacturing product process and high compressibility, superior dilution properties and rapid disintegrating |
| Spray granulated d-mannitol and croscarmellose sodium | Parateck® odt | Merck kгаа | Directly compressible excipient designed for orally disintegrating tablets and provided rapid disintegration and exceptional strength as well as a pleasant taste and mouthfeel |
| Hypromellose and lactose | Retalac® | Meggle | Improved flow and bendability, enhancing compatibility in direct compression |

| | | | |
|--|------------------|------------------------------------|--|
| 70 % alpha-lactose monohydrate, 20 % microcrystalline cellulose (mcc) and 10 % white, native corn starch | Combilac® | Meggle | Improved compaction properties compared to an equivalent admixture of individual ingredients, providing robust tablets with minimal friability, and assuring rapid, hardness independent tablet disintegration for effective api release |
| Microcrystalline cellulose, colloidal silicon dioxide, mannitol, fructose, crospovidone | Prosolv® odt g2 | Rs pharma | Smooth and creamy mouthfeel, Excellent flowability, excellent blending characteristics for improved content uniformity, High patient compliance |
| Crospovidone, dextrose monohydrate, mannitol, monohydrate lactose | Disintequik™ odt | Kerry | Direct tableting operations for use in orally disintegrating tablets. It can be blended with a flavor, active, suitable lubricant, additional sweetener if desired |
| Microcrystalline cellulose, monohydrate lactose | Disintequik mcc | Kerry | Direct tableting operations where hard tablets and fast disintegration are required. |
| Carmellose, crospovidone, mannitol, microcrystalline cellulose | Granfiller-d | Daicel group and nichirin-chem | Direct compression odt, high tablet hardness and rapid disintegration |
| Calcium carbonate & polyvinyl pyrrolidone | Dicom-dc® s-604 | Gangwal healthcare private limited | Excellent flowability, better compressibility & uniform particle size distribution. |
| Sucrose 3%, dextrin microcrystalline Cellulose, silicon dioxide | Dipa prosolv | Penwest pharmaceuticals company | Directly compressible, better flow, reduced sensitivity to Wet granulation, better hardness of tablet, reduced friability |
| Lactose and cellulose | Cellactose | Meggle | High compressibility, good mouth feels, better tableting at low cost |
| Sucrose and dextrin | Dipac | Penwest pharm | Directly compressible grade |
| Microcrystalline cellulose and silicon dioxide | Prosolv | Penwest pharmaceuticals | Better flow, reduced sensitivity to wet granulation, better hardness of tablet, reduced friability |
| Microcrystalline cellulose and guar gum | Avicel ce-15 | Fmc corp. | Less grittiness and minimal chalkiness |
| Calcium carbonate and sorbitol | Formaxx | Merck | High compressibility, excellent taste masking, free flow, superior content uniformity, controlled particle size distribution |
| Microcrystalline cellulose and lactose | Microcelac | Meggle | Capable of formulating high dose, small tablets with Poorly flowable active ingredients |
| Lactose and maize starch | Starlac | Meggle | Good flowability due to spray drying, the acceptable crushing force due to lactose content and rapid disintegration |

| | | | |
|------------------------------------|------------|------------------------------|--|
| Lactose,3.2%kallidone kallidone cl | Ludipress | Basfag,ludwigshafen ,Germany | Low degree of hygroscopicity, good flowability, tablet hardness independent of machine speed |
| Lactose,25% cellulose | Cellactose | Meggleg mbh&co.Kg, Germany | Highly compressible, good Mouthfeel, better tableting at low cost |

5. Conclusion

Co-processed excipients play important roles in direct compression of tablet dosage forms providing improved physical, chemical and mechanical properties. The Co-processed excipient helps to overcome the problem related to the use of a single excipient and gives rise to the preparation of various novel formulations. These excipients show rapid disintegration, good flow properties, high compressibility, and improve hardness of tablets. Considerable research must be done in areas of coprocessing of excipients used in direct compression of tablets.

Compliance with ethical standards

Acknowledgments

Would like to thank Dr. M. Sunitha Reddy and K. A. Vijetha for proper Guidance and support and the Department of Pharmaceutics, Centre for Pharmaceutical Sciences, JNTUH UCEST, and JNTUH. For providing lab facilities for this research work.

Disclosure of conflict of interest

All the authors declare no conflict of interest.

References

- [1] Chaudhari PD, Phatak AA, Desai U. A review: co processed excipients-an alternative to novel chemical entities. International Journal of Pharmaceutical and chemical sciences. 2012 Oct, 1(4):1480-98.
- [2] Bin LK, Gaurav A, Mandal UK. A review on co-processed excipients: current and future trend of excipient technology. Int J Pharm Sci. 2019.
- [3] Pawar SB, Ahirrao SP, Kshirsagar SJ, City BK, Knowledge B. Review on novel pharmaceutical co-processed excipients. Pharm. Reson. 2019, 2:14-20.
- [4] Adeps R, Brahmaiah B, Nama S, Desu PK. International Journal of Current Trends in Pharmaceutical Research. Pharm. Res. 2013, 1(2).
- [5] Zade A, Wani M, Limaye D, Patil R, Patil P, Baheti A, Polshettiwar S, Tagalpallewar A. A systematic review on Co-processed formulation and development. Annals of the Romanian Society for Cell Biology. 2021 Apr 30:17140-7.
- [6] Bin LK, Hui HS, Uddin AH, Sarker ZI, Ling CY. Co-processed Excipients: A Revisit of Its Development in the Past Two Decades, A Review. Journal of Pharmaceutical Negative Results. 2022 Oct 11:96-103.
- [7] Dziemidowicz K, Lopez FL, Bowles BJ, Edwards AJ, Ernest TB, Orlu M, Tuleu C. Co-processed excipients for dispersible tablets—part 2: Patient acceptability. AAPS Pharm SciTech. 2018 Aug, 19:2646-57.
- [8] Chougule AS, Dikpati A, Trimbake T. Formulation development techniques of co-processed excipients. Journal of Advanced Pharmaceutical Sciences. 2012, 2(2):231-49.
- [9] Chowdary KP, Ramya K. Recent research on co-processed excipients for direct compression-A Review. Pharmacie Globale. 2013 Feb 1, 4(2):1.
- [10] Gangurde HH. Co-Excipient: Future of Formulation Industry. Acad J Polym Sci. 2019, 3(3):54-9.
- [11] Garg N, Pandey P, Kaushik D, Dureja H. Development of novel multifunction directly compressible co-processed excipient by melt granulation technique. International journal of pharmaceutical investigation. 2015 Oct, 5(4):266.

- [12] Olayemi OJ, Nock-Anyebe S. Evaluation of Novel co-processed excipient for fast disintegration of aspirin tablet formulations. *Journal of Pharmacy & Bioresources*. 2021 May 28, 18(1):1-1.
- [13] Patel H, Gohel M. A review on development of multifunctional co-processed excipient. *J Crit Rev*. 2016, 3(2):48-54.
- [14] Gandhi PP, Mundada AS. Formulation and evaluation of coprocessed excipient for mouth dissolving formulation. *Int J Drug Dev Res*. 2016, 8(1):30-5.
- [15] Ramya K, Chowdary KP. Preparation, characterization and evaluation of a new coprocessed excipient as directly compressible vehicle in tablet formulation. *Journal of Global Trends in Pharmaceutical Sciences*. 2013 Oct, 4(4):1322-8.
- [16] Desai U, Chavan R, Mhatre P, Chinchole R. A review: coprocessed excipients. *International Journal of Pharmaceutical Sciences Review and Research*. 2012 Jan, 12(2):102.
- [17] Marwaha M, Sandhu D, Marwaha RK. Coprocessing of excipients: a review on excipient development for improved tableting performance. *International Journal of Applied Pharmaceutics*. 2010 Apr, 2(3):41-7.
- [18] Gohel MC, Jogani PD. A review of co-processed directly compressible excipients. *J Pharm Pharm Sci*. 2005 Apr 16, 8(1):76-93.
- [19] Reimerdes D, Aufmuth KP. Tableting with co-processed lactose-cellulose excipient. *Manufacturing chemist*. 1992 Dec, 63(12):21.
- [20] Jivraj M, Martini LG, Thomson CM. An overview of the different excipients useful for the direct compression of tablets. *Pharmaceutical science & technology today*. 2000 Feb 1, 3(2):58-63.